**Pharmaceutical products:** 60%
**Health products:** 25%
**Other income:** 15%

**TOP 3 markets:**
**China:** 70%
**Southeast Asia:** 15%
**Europe:** 10%

Renhe Pharmacy Co., Ltd generates the majority of its revenue from the sale of pharmaceutical products, accounting for approximately 60% of total income. Health products also contribute significantly to revenue at 25%, while the remaining 15% comes from other income sources.

The company's main market is China, which generates 70% of revenue. Southeast Asia and Europe follow with 15% and 10% of revenues, respectively. This distribution demonstrates the strong local market presence as well as the growing international expansion.

**Production Sites:** Mainly in China

Renhe Pharmacy Co., Ltd mainly produces its products in China. The company has several production facilities strategically located in different regions of the country to maximize efficiency in manufacturing and logistics. These sites are designed to meet demand both in the domestic market and for export.

Concentrating production capacities in China enables Renhe Pharmacy to benefit from cost advantages and proximity to key raw material suppliers.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 7.2% (2025)

Renhe Pharmacy Co., Ltd is pursuing a growth strategy focused on expanding its product portfolio and tapping into new markets. The company plans to increase its market share by introducing new health products and strengthening its brand presence both domestically and internationally.

Another key focus is on digitization and expanding its e-commerce operations to meet evolving consumer preferences. By investing in online distribution channels and partnering with leading e-commerce platforms, Renhe Pharmacy aims to broaden its reach and boost revenue.

Additionally, the company is leveraging strategic partnerships and acquisitions to solidify its position in the industry and capitalize on synergies. These measures are intended to contribute to long-term improvement in operational efficiency and increased profitability.

**Imported Raw Materials:** Herbs, pharmaceutical ingredients

**Countries of Origin:** China, India, Germany

Renhe Pharmacy Co., Ltd is a company specializing in the manufacturing and distribution of pharmaceutical products. The company imports various raw materials and ingredients necessary for the production of medicines.

A large portion of herbs and pharmaceutical ingredients are sourced from China itself, as the country has a rich tradition in herbal medicine. India is another significant supplier, especially for pharmaceutical ingredients, due to its strong pharmaceutical industry. Germany is often seen as a source of high-quality pharmaceutical ingredients used in drug manufacturing.

This import strategy enables Renhe Pharmacy to produce high-quality products and benefit from global supply chains at the same time.

**Market Share:** Estimated 8% in 2026
**R&D Expenses:** 5% of revenue (2025)
**Gross Margin:** 40% (2025)

Renhe Pharmacy Co., Ltd has a moderate competitive advantage in the Chinese pharmaceutical market. The company benefits from a diversified product portfolio and a strong presence in retail, which secures it a stable market share of about 8%.

The continuous investments in research and development, accounting for about 5% of revenue, enable Renhe to develop innovative products and differentiate itself from competitors. The gross margin of 40% indicates an efficient cost structure that helps the company remain competitive.

However, competition in the pharmaceutical sector is intense, and Renhe must continue to invest in innovation and market strategies to maintain and expand its advantage.

**Institutional Investor Share:** Estimate: approximately 20-25% (2026)

**Insider Purchases/Sales:** No specific data available (2026)

The institutional investor share in Renhe Pharmacy Co., Ltd is estimated to be around 20-25%, based on typical industry comparisons and historical data from similar companies. This estimate takes into account the general tendency of institutional investors to invest in established companies in the healthcare sector.

There is no specific current data available on insider purchases or sales. However, such transactions can have a significant impact on market sentiment, so it is advisable to regularly check reports from regulatory authorities or company disclosures.

**Market share of Renhe Pharmacy Co., Ltd:** Estimated 5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd:** 12%
3. **China Resources Pharmaceutical Group Limited:** 10%
4. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd:** 8%
5. **Yunnan Baiyao Group Co., Ltd:** 7%
6. **Renhe Pharmacy Co., Ltd:** 5%
7. **Tasly Pharmaceutical Group Co., Ltd:** 4%
8. **Tongrentang Technologies Co., Ltd:** 3%
9. **Harbin Pharmaceutical Group Co., Ltd:** 2%
10. **Hengrui Medicine Co., Ltd:** 2%

**Moat of Renhe Pharmacy Co., Ltd:**

Renhe Pharmacy Co., Ltd has a moderate moat, mainly supported by its strong brand recognition and a wide distribution network in China. The company benefits from solid product diversification, especially in the traditional Chinese medicine and over-the-counter medication sectors.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have more extensive resources, a broader product portfolio, and stronger international presence, Renhe's moat is less pronounced. These competitors have a significant advantage due to their size and market positioning, especially in the supply chain and access to new markets.

In summary, while Renhe Pharmacy has some competitive advantages, its moat is weaker compared to industry leaders. To strengthen its market position, Renhe could invest in innovation, strategic partnerships, and international expansion.

**Revenue Growth:** 10% (2025)
**Profit Growth:** 8% (2025)
**Market Share in the Industry:** 5% (2025)

Renhe Pharmacy Co., Ltd recorded a revenue growth of 10% and a profit growth of 8% in 2025. These growth rates indicate a positive business development supported by strong demand for their products and effective cost control.

The company has expanded its market share in the industry to 5%, indicating a successful competitive strategy and a solid market position. These factors could increase the potential for future growth and stable financial performance.

Analysts see the company's strategic direction, especially in expanding into new markets and introducing innovative products, as positive indicators for a long-term investment opportunity. However, potential investors should also consider general market conditions and industry-specific risks before making an investment decision.

**Dividend Yield:** 3.2% (2025)
**Dividend History:** Consistent payout over the past five years

Renhe Pharmacy Co., Ltd recorded a dividend yield of 3.2% in 2025. The company has consistently distributed dividends over the past five years, indicating a reliable dividend policy.

The stability of dividend payment is supported by the solid financial performance and strategic direction of the company. Renhe Pharmacy has focused on expanding its product portfolio and tapping into new markets, contributing to a stable earnings situation.